Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 May 20:8:18.
doi: 10.1186/1471-2393-8-18.

Multiplex ligation-dependent probe amplification versus karyotyping in prenatal diagnosis: the M.A.K.E. study

Elisabeth M A Boormans  1 , Erwin Birnie, Hajo I Wildschut, Heleen G Schuring-Blom, Dick Oepkes, Carla A C van Oppen, Jan G Nijhuis, Merryn V E Macville, Angelique J A Kooper, Karin Huijsdens, Mariëtte V J Hoffer, Attie Go, Johan Creemers, Shama L Bhola, Katia M Bilardo, Ron Suijkerbuijk, Katelijne Bouman, Robert-Jan H Galjaard, Gouke J Bonsel, Jan Mm van Lith
Affiliations
Clinical Trial

Multiplex ligation-dependent probe amplification versus karyotyping in prenatal diagnosis: the M.A.K.E. study

Elisabeth M A Boormans et al. BMC Pregnancy Childbirth. .

Abstract

Background: In the past 30 years karyotyping was the gold standard for prenatal diagnosis of chromosomal aberrations in the fetus. Traditional karyotyping (TKT) has a high accuracy and reliability. However, it is labor intensive, the results take 14-21 days, the costs are high and unwanted findings such as abnormalities with unknown clinical relevance are not uncommon. These disadvantages challenged the practice of karyotyping. Multiplex ligation-dependent probe amplification (MLPA) is a new molecular genetic technique in prenatal diagnosis. Previous preclinical evidence suggests equivalence of MLPA and traditional karyotyping (TKT) regarding test performance.

Methods/design: The proposed study is a multicentre diagnostic substitute study among pregnant women, who choose to have amniocentesis for the indication advanced maternal age and/or increased risk following prenatal screening test. In all subjects, both MLPA and karyotyping will be performed on the amniotic fluid sample. The primary outcome is diagnostic accuracy. Secondary outcomes will be maternal quality of life, women's preferences and costs. Analysis will be intention to treat and per protocol analysis. Quality of life analysis will be carried out within the study population. The study aims to include 4500 women.

Discussion: The study results are expected to help decide whether MLPA can replace traditional karyotyping for 'low-risk' pregnancies in terms of diagnostic accuracy, quality of life and women's preferences. This will be the first clinical study to report on all relevant aspects of the potential replacement.

Trial registration: The protocol is registered in the clinical trial register number ISRCTN47252164.

PubMed Disclaimer

References

    1. Working Party Prenatal Diagnosis and Fetal Therapy Annual Report 2003 Working Party Prenatal Diagnosis and Fetal Therapy. 2003.
    1. The Hague HCN. Prenatal Screening: Down's syndrome, neural tube defects, routine-ultrasonography. 2001.
    1. Midtrimester amniocentesis for prenatal diagnosis. Safety and accuracy. JAMA. 1976;236:1471–1476. doi: 10.1001/jama.236.13.1471. - DOI - PubMed
    1. Los FJ, van den BC, Wildschut HI, Brandenburg H, den Hollander NS, Schoonderwaldt EM, Pijpers L, Jan HG, Van Opstal D. The diagnostic performance of cytogenetic investigation in amniotic fluid cells and chorionic villi 2. Prenat Diagn. 2001;21:1150–1158. doi: 10.1002/pd.194. - DOI - PubMed
    1. Grimshaw GM, Szczepura A, Hulten M, MacDonald F, Nevin NC, Sutton F, Dhanjal S. Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities 4. Health Technol Assess. 2003;7:1–146. - PubMed

MeSH terms

Associated data